The main mul­ti­ple myeloma-related poster session at this year's Amer­i­can Society of Clinical Oncology (ASCO) annual meeting in Chicago took place last Monday. Several of the posters pre­sented during that session focused on poten­tial new mul­ti­ple myeloma ther­a­pies. Those posters were reviewed in the Beacon's previous ASCO mul­ti­ple myeloma up­date.

In this, the Beacon's final ASCO 2016 up­date, the attention shifts to posters from the Monday session that were re­lated to existing myeloma ther­a­pies, as well as a pair of posters re­lated to smol­der­ing mul­ti­ple myeloma.

The posters about existing ther­a­pies …

Die Jahrestagung der amerikanischen Gesellschaft für Klinische Onkologie (ASCO) hat letzten Freitagmorgen begonnen und wird bis Dienstag, den 7. Juni, dauern.

Jeden Tag finden Vorträge über das multiple Myelom statt. Freitag wurden die meisten Vorträge mit neuen Forschungsergebnissen über das Myelom gehalten. Es gab neun Vorträge während einer einzelnen Nachmittagssitzung, die sich auf das multiple Myelom konzentrierten.

Außerdem gab es am Samstag, Sonntag und Montag Fortbildungssitzungen über das multiple Myelom. Darüber hinaus gab es am Sonntag eine Sitzung mit sogenannten late-braking abstracts (hochaktuellen Zusammenfassungen), die eine Präsentation über wichtige, neue Forschungsergebnisse über …

This year’s American Society of Clinical Oncology (ASCO) annual meeting began the morning of last Friday, and the meeting will run through Tues­day.

Multiple myeloma-related pre­sen­ta­tions are taking place every day of the meeting. Friday, how­ever, was the busiest day at the meeting in terms of oral pre­sen­ta­tions with new myeloma-related re­search. There were nine such pre­sen­ta­tions during a single afternoon session focused on multiple myeloma.

In addi­tion, there were myeloma-related education session pre­sen­ta­tions on Saturday, yesterday, and today. There also was a late-breaking ab­stract session yesterday (Sunday) with one pre­sen­ta­tion that …

How has your week been, myeloma world?

Summer definitely is here at Myeloma Morning Headquarters. We had temper­a­tures yesterday and today that rival those normally seen in early August.

We're not exactly sure how we feel about this devel­op­ment.

As for myeloma-related news, we have a lot of ground to cover.

We have one new myeloma research study that we summarize at length. It's about a difficult subject, namely, the impact of early relapse on the over­all survival of multiple myeloma patients. It's a difficult subject be­cause, not surprisingly, early re­lapse con­tinues …

Cambridge, MA and Osaka, Japan (Press Release) – Takeda Pharma­ceu­tical Company Limited (TSE: 4502) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a negative opinion, recommending against the authori­za­tion of NINLARO® (ixazomib) capsules, an oral pro­te­a­some inhibitor for the treat­ment of patients with re­lapsed and/or refractory multiple myeloma. Takeda intends to appeal this opinion and request a re-examination by the CHMP.

“We are disappointed by the CHMP’s opinion. With the sup­port of European key medical experts, we will con­tinue our efforts work­ing …

We tried, myeloma world, but we couldn't come up with a short title for today's report.

There were just too many words needed to describe the three research articles that we plan to review with you in this edition of Myeloma Morning.

First, we have an important new study out of Spain that in­ves­ti­gates the sig­nif­i­cance of Bence Jones protein in smol­der­ing multiple myeloma patients.

Next, we turn to a study by researchers in Japan. They in­ves­ti­gate different methods for measuring a person's bone marrow plasma cell per­cent­ages, and how those methods can …

The results of an important Ninlaro (ixazomib) clin­i­cal trial have been published in a leading medical journal.

The "TOURMALINE-MM1" trial was instrumental in gaining Ninlaro ap­proval in the United States as a new treat­ment for multiple myeloma. The Phase 3 trial tested whether adding Ninlaro to Revlimid (lena­lido­mide) and dexa­metha­sone is safe and im­proves treat­ment out­comes in patients with re­lapsed multiple myeloma

Up until now, only limited results of the TOURMALINE-MM1 trial have been publicly avail­able. Some can be found in Ninlaro's pre­scrib­ing in­­for­ma­tion. …